

REVIEW

Open Access



# Therapeutic role of curcumin and its novel formulations in gynecological cancers

Mohammad Hossein Pourhanifeh<sup>1</sup>, Maryam Darvish<sup>2\*</sup>, Javad Tabatabaeian<sup>3</sup>, Mahboobeh Rabbani Fard<sup>3</sup>, Reza Mottaghi<sup>4</sup>, Mohammad Javad Azadchehr<sup>5</sup>, Moghaddaseh Jahanshahi<sup>6</sup>, Amirhossein Sahebkar<sup>7,8</sup> and Hamed Mirzaei<sup>9\*</sup>

## Abstract

Gynecological cancers are among the leading causes of cancer-associated mortality worldwide. While the number of cases are rising, current therapeutic approaches are not efficient enough. There are considerable side-effects as well as treatment resistant types. In addition, which all make the treatment complicated for afflicted cases. Therefore, in order to improve efficacy of the treatment process and patients' quality of life, searching for novel adjuvant treatments is highly warranted. Curcumin, a promising natural compound, is endowed with numerous therapeutic potentials including significant anticancer effects. Recently, various investigations have demonstrated the anticancer effects of curcumin and its novel analogues on gynecological cancers. Moreover, novel formulations of curcumin have resulted in further propitious effects. This review discusses these studies and highlights the possible underlying mechanisms of the observed effects.

**Keywords:** Curcumin, Nanocurcumin, Endometrial cancer, Ovarian cancer, Cervical cancer, Curcumin derivatives, Natural compound

## Background

Natural compounds like curcumin, epigallocatechin gallate (EGCG), quersetin, and resveratrol, have been shown to modulate some genetic and epigenetic mechanisms, which may increase sensitivity of cancer cells to conventional agents and thus inhibit tumor growth [1, 2]. Curcumin, the main bioactive ingredient of turmeric, has been revealed to possess various therapeutic potentials, such as anti-tumor [3, 4], anti-atherosclerotic [5, 6], anti-microbial [7], anti-oxidant [8], and anti-inflammatory [9–11]. A wide variety of molecular targets have been reported for curcumin, including some

transcription factors, gene modulators, kinases, growth factors, and cell membrane receptors [12–16]. Due to its various and pleiotropic functions, increasing number of studies has been focused on curcumin, specifically in malignancies.

Numerous investigations have shown that curcumin acts as a beneficial adjuvant and chemopreventive agent for cancer [17]. Notably, human studies have demonstrated the tolerability, safety and anti-carcinogenic ability of this compound for humans [13, 14]. The promising outcome of these studies has helped to raise the hope for a brighter future in cancer treatment.

Gynecologic cancers include an unlimited and abnormal cell growth, developing in female reproductive system, such as endometrial, ovarian, cervical, primary peritoneal, vulvar and vaginal malignancies. According to reports, more than 1 million patients were newly diagnosed, and more than 580 000 mortalities occurred because of endometrial, cervical, and ovary cancers in

\* Correspondence: [maryam\\_darvish@yahoo.com](mailto:maryam_darvish@yahoo.com); [h.mirzaei2002@gmail.com](mailto:h.mirzaei2002@gmail.com); [mirzaei-h@kaums.ac.ir](mailto:mirzaei-h@kaums.ac.ir)

<sup>2</sup>Department of Medical Biotechnology, Faculty of Medicine, Arak University of Medical Science, Arak, Iran

<sup>9</sup>Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

2018 [15]. While endometrial and cervical cancers are diagnosed in early stages, ovarian cancer is usually diagnosed in more advanced stages, when treatment is more challenging [16, 18]. Despite all the developments in cancer therapy and emergence of novel treatments, these cancers still have considerable mortality rates. Therefore, introducing novel agents which can potentially improve the therapeutic outcome for these affected patients is highly needed. Here, in this review we focus on current evidence for the efficacy of curcumin and its novel formulations in gynecological cancers.

### The role of curcumin in gynecological cancers

In terms of gynecological cancers, curcumin has been shown to modify the effects of risk factors during the course of cancer progression and since the very beginning. Some of those well-known risk factors are obesity, smoking, estrogen and human papillomavirus (HPV) infections [19, 20]. Interestingly, curcumin has been shown to reduce estrogen synthesis, estrogen-derived DNA damage, inflammation in the adipose tissue, and inhibit E6 and E7 onco-protein expression in HPV [19].

According to *in vitro* studies, curcumin can prevent invasion and migration of endometrial carcinoma (EC) cell and plays an anti-metastatic role due to a reduction in the production and function of matrix metalloproteinases-2 and -9 (MMP-2 and MMP-9). Degradation of tumor extracellular matrix by these enzymes is a possible cause of metastasis and invasion of myometrial cancer to lymph node in type II EC. Curcumin has been shown to suppress the ERK signaling pathway and decrease the expression of these enzymes [21].

Curcumin has been reported to induce apoptosis in ovarian cancer cells, through P53-independent pathway, but similar to wild-type P53 cells. Curcumin-treated HEY cells showed poly (ADP-ribose) polymerase-1 cleavage, DNA fragmentation, nuclear fragmentation and condensation, indicating the induction of cell apoptosis. Moreover, curcumin is able to induce apoptosis through both intrinsic and extrinsic mechanisms. The expression of antiapoptotic regulators, survivin and Bcl-2, was decreased following an increase in the activity of p38 protein, mitogen-activated protein kinases (MAPK). The anticancer cell death caused by curcumin was reported to also occur through suppressing the prosurvival Akt signaling in different ovarian cancer cells [22]. The expression of urokinase-type plasminogen activator (uPA) was reportedly blocked by curcumin in highly invasive human ovarian cancer cell line, HRA, which has a role in cancer metastasis. uPA is a serine protease expressed via Src-MAPK/ERK-AP-1 and Src-MAPK/ERK-PI3K/ Akt-NF-kB pathways in response to TGF- $\beta$ 1, where curcumin inhibits the AP-1 complex formation [22]. Accordingly, curcumin can potentially improve the

outcome in advanced gynecological cancers impeding cancer invasion and progression [23]. In the following sections, we discuss recent investigations on curcumin therapy for endometrial, cervical and ovarian cancer.

### Curcumin and endometrial cancer

Endometrial cancer (EC), the most frequent malignant tumor of the genital tract in females, occurs in peri- and postmenopausal women [24, 25]. It is estimated that more than 50,000 new cases were diagnosed, and about 8,500 cases were expired due to this malignancy in the US in 2014. Recently, due to the life style changes, gynecological cancers are causing increasing mortalities [26]. The majority of affected individuals are diagnosed early and usually cured with surgery alone or in combination with radiotherapy [27]. However, mortality rate of this cancer has experienced a sharper rise than its incidence over the last decades [28–31]. Despite all the development in therapeutic strategies for this malignancy, end-stage patients face poor prognoses, and the 5-year survival rate is as low as 25–45% [26]. Additionally, the current therapeutic approaches are not effective for 15% of patients who show aggressive phenotype [27].

It was reported that in a 30-day *in vivo* investigation, daily intraperitoneal administration of 50 mg/kg curcumin decreased the volume of tumor five-fold in comparison with that in vehicle-treated animals [32]. Sirohi and his colleagues also carried out *in vitro* experiments utilizing both HEC-1B and Ishikawa cells and indicated that curcumin exhibits its anti-migratory impacts *via* increasing the Slit2 expression [32]. Slit2 induction downregulated the expression of migratory proteins, including the matrix metalloproteases MMP2/9, stromal cell-derived factor-1 (SDF-1), and CXCR4 (chemokine receptor 4) in EC cells [32]. This study indicated that curcumin suppresses tumor growth and inhibits proliferation of EC cells [32]. It also mediates ROS-induced apoptosis and shows inhibitory effects on migration of Hec-1B and Ishikawa cells through Slit-2-induced downregulation of MMP-2 and -9, SDF-1, and CXCR4 [32].

Androgen receptors (ARs) are ligand-dependent nuclear transcription factors which have been related to various tumors types, including endometrial, liver, bladder, and prostate tumors [33]. It has been demonstrated that curcumin dose- and time-dependently increases apoptosis and blocks proliferation of EC cell line RL-952 [34]. Curcumin also targeted Wnt pathway, which plays a crucial role in tumor proliferation and progression, and subsequently declined the expression of AR in cancer cells [34]. In a research carried out by Chen et al. [21], it was shown that curcumin inhibits the invasion and migration of endometrial carcinoma cells. Additionally, it decreased the proteinase activity and matrix metalloproteinase (MMP)-2 and -9 expression [21].

Curcumin in combination with ERK inhibitor U0126 synergistically reduced the expression of MMP-2/-9, leading to inhibit the cancer cells invasion [35]. Sun et al. illustrated that, in addition to suppression of EC cell invasion via downregulating MMP-2, curcumin inhibits their proliferation as well [35]. Feng et al. revealed that curcumin suppresses the apoptosis and proliferation of human endometrial carcinoma cells through downregulating the expression of AR *via* Wnt pathway [34]. Table 1 shows the available data about the effects of curcumin in EC therapy.

**Curcumin and cervical cancer**

Cervical cancer is the third most prevalent malignancy and the fourth leading cause of cancer-related mortality in women [44]. Nowadays, its incidence is triggering the younger females [45]. Patients who are still at early stages have good prognosis and successfully respond to

conventional treatments, including chemoradiation and/or surgery [46]. While these standard therapies could cause serious damages to vaginal and ovarian functions [47], patients with extrapelvic ingagement have 5-year survival rate of 17%, and in women with recurrent disease this rate is less than 5% [48]. Human papilloma virus (HPV) infection is the initial step in most of the cervical cancer cases [49]. In addition to chronic infection with HPV, smoke carcinogen (benzo [a]pyrene) and cigarette smoking are considered as major risk factors related to cervical cancer [50, 51].

Curcumin has revealed concentration-dependent chemotherapeutic and chemopreventive impacts in a number of investigations [52]. Curcumin exerts cytotoxic effects in cervical cancer cells in a time- and dose-dependent approach, especially in HPV-infected cells [53]. It has been confirmed that, *via* selectively suppressing activator protein 1 (AP-1) activity, curcumin

**Table 1** Performed studies on curcumin and EC therapy

Type of curcumin	Dose	Target(s)	Effect(s)	Type of cell line	Ref
Curcumin	6 μM	CTGF, MMP-2, -9 Slit-2, CXCR4, SDF-1, MMP9	Induction of apoptosis Inhibition of tumor proliferation, migration, invasion, and growth	Ishikawa Hec-1B	[32]
	6 μM for 48h	-	Induction of ROS production	Ishikawa cell	[32]
	50 mg/kg	-	Reduction the tumor volume in mice	-	[32]
	30 μmol/L	MMP-2	Curcumin can suppress invasion and proliferation of endometrial cancer cell	Ishikawa	[35]
	50 μM	STAT-3 PIAS-3	Curcumin can inhibit JAK-STAT signaling through PIAS-3 activation	RL95-2 Ishikawa OVCA cell	[36]
	30 μM for 120h	TREK1	Curcumin has an antiproliferative effect on endometrial cells.	Ishikawa	[37]
	30 μM	MMP-2, -9 ERK	Curcumin can suppress invasion and proliferation of endometrial cancer cells through inhibition of MMP-2 and MMP-9 and the ERK signaling pathway	HEC-1B	[21]
	300 mg/kg.d	Bcl-2	Curcumin inhibits the Bcl-2 expression	-	[38]
	40 to 60 μM for 3h	Ets-1 Bcl-2	Curcumin can decrease the Bcl-2 and Ets-1 expression and induces apoptosis.	HEC-1-A	[39]
	100 μM/L	Androgen receptor (AR)	Curcumin can suppress apoptosis and proliferation of endometrial cancer cells through decreasing expression of androgen receptor	NA	[34]
112.5 μM	-	Curcumin has an antiproliferative effect on MCF-7, MG-63 and MDA-MB-231 cells	MDA-MB- 231 MCF-7 MG-63	[40]	
Curcumin loaded amphiphilic mixed micelles	10 μM	Survivin Bcl-2 PARP	Inhibition of tumor growth, Apoptosis induction	Ishikawa	[41]
Liposomal Curcumin	NA	NF-κB	Inhibition of tumor growth	Ishikawa HEC-1	[42]
Curcumin Phytosome	2 g/day	-	Immunomodulatory effects	-	[43]

downregulates HPV18 transcription, which reverses the *fra-1* and *c-fos* expression dynamics in cervical cancer cells [53]. Higher suppressive function of curcumin against cervical cancer is because of the inhibition of the mitochondrial pathway, iNOS, COX-2, and cyclin D1 activity, and ERK and Ras signaling pathways as well as telomerase action [54, 55]. Remarkably, curcumin acts through targeting several signaling pathways, making the proliferation of cervical cancer cells revert to normal. It also mediates important alterations in tumor-associated proteins correlated with cell metabolism, cell cycle, and carcinogenicity in HeLa cells [56].

He and co-workers reported that both curcumin-photodynamic therapy (PDT) and dual antiplatelet therapy (DAPT), a Notch receptor blocker, are capable of inducing apoptosis and blocking the proliferation of cervical cancer Me180 cells [57]. Moreover, DAPT has synergistic effects on curcumin-PDT in cervical cancer treatment, which is primarily associated with NF- $\kappa$ B and Notch-1 down-regulation [57]. Ghasemi et al. recently performed an *in vitro* study to evaluate the probable mechanisms related to anticancer effects of curcumin on cervical cancer cell line [58]. They revealed that curcumin suppresses proliferation and invasion of cervical cancer cells through Wnt/ $\beta$ -catenin and NF- $\kappa$ B pathways impairment [58]. Shang and colleagues reported that, 13  $\mu$ M curcumin induces cell death in HeLa cells via induction of DNA damage and chromatin condensation [59]. It has been demonstrated that curcumin in combination with ultrasound exerts more beneficial effects against cervical cancer cells [60]. Carr et al. indicated that this combination enhanced apoptosis in SiHa or HeLa cells [60]. Curcumin alone caused less necrosis compared to the combination therapy. They showed the ultrasound capacity to elevate curcumin effectiveness [60]. Recently, it has been reported that curcumin elevates intracellular ROS levels in cervical cancer cells, but not in healthy epithelial cells [61]. This effect leads to inhibition of ER stress and partly restoration of the viability in cancer cells treated with curcumin [61]. Collectively, these observations show that curcumin promotes ER stress-mediated apoptosis in cervical cancer cells through increasing the cell type-specific ROS generation [61]. According to Yoosungnoen-Chintana's report, curcumin at high doses (1,000 and 1,500 mg/kg) inhibits angiogenesis as well as tumor growth in CaSki-implanted mice possibly induced *via* downregulating the EGFR, COX-2 and VEGF expression [62]. Table 2 shows the available findings on curcumin therapy for cervical cancer *in vivo* and *in vitro*.

#### Curcumin and ovarian cancer

In the western world, ovarian cancer leads to the greatest mortality rate among all the gynecologic cancers.

Affected individuals are usually diagnosed too late at advanced stages, when the cancer has spread to the peritoneal surfaces [96–98]. Surgery is the most efficient therapy for advanced stages, and is preceded by chemotherapy with paclitaxel and carboplatin. After three chemotherapy cycles, interval cytoreductive surgery is alternatively done [96–98].

Curcumin reduces the needed dose of radiation and cisplatin in growth suppression of cisplatin-resistant ovarian cancer cells [99]. Curcumin, in combination with low amounts of cisplatin, also promotes apoptosis [99]. The decrease of cisplatin resistance in ovarian cancer cells by curcumin is probably through regulating extracellular vesicle-induced transfer of miR-214 and maternally expressed 3 (MEG3) [100]. This polyphenol has cytotoxic effects against platinum-resistant OVCAR-3 cells, which can be significantly enhanced by the compound Y15 (1, 2, 4, 5-benzene tetra amine tetrahydrochloride) [101]. Moreover, it decreases the number and size of ovarian tumors through inhibiting STAT3 and NF- $\kappa$ B signaling and inducing nuclear factor erythroid 2/heme oxygenase1 (Nrf2/HO-1) pathway [102]. In addition, curcumin induces G2/M cell-cycle arrest in cisplatin-resistant ovarian cancer cells *via* increasing apoptosis and phosphorylation of p53 by caspase-3 activation followed by poly (ADP-ribose) polymerase-1 (PARP) degradation [103].

In human ovarian cancer cell lines A2780 and SK-OV-3, curcumin is able to induce apoptosis as well as protective autophagy *via* suppression of AKT/mTOR/p70S6K pathway, demonstrating the synergistic impacts of curcumin and autophagy suppression [104]. Curcumin inhibits the activity of Sarco/endoplasmic reticulum calcium ATPase (SERCA) leading to dysregulation in Ca<sup>2+</sup> homeostasis; and hence, contributes to apoptosis in ovarian cancer cells [105]. As discussed before, curcumin has anti-proliferative effects and can restrict tumor growth by this potential. Shi and colleagues demonstrated, in addition to apoptosis induction, 40  $\mu$ M curcumin suppressed the growth of ovarian cancer cells [106]. Lin et al. showed that, in addition to apoptosis induction and anti-proliferative effects, curcumin suppresses angiogenesis in ovarian cancer *in vivo* and *in vitro* [107]. Furthermore, curcumin is capable of suppressing endothelial growth factor (EGF)-mediated Aquaporin 3 up-regulation and cell migration in CaOV3 ovarian cancer cells through its inhibitory impacts on EGFR and AKT/ERK activation [108]. In an *in vitro* investigation, Xiaoling et al. reported that curcumin inhibits the metastasis and invasion of the human ovarian cancer cells SKOV3 through suppressing CXCR4 and CXCL-12 expression [109]. Wahl and his colleagues illustrated that combined treatment of Apo2 ligand (Apo2L)/TNF-related apoptosis-inducing ligand and curcumin (5–15  $\mu$ M) leads to

**Table 2** Conducted investigations on the treatment of cervical cancer with curcumin

Type of curcumin	Dose	Main target (s)	Main effect (s)	Model (in vivo/ in vitro/human)	Cell line	Ref
Curcumin	20 μM for 72h	N-cadherin, Vimentin, Slug, PIR, Pirin	Inhibition of cancer cell growth, migration, invasion Inhibition of angiogenesis	In vitro	SiHa	[63]
	2.5, 5 μmol/L In vivo (150-200 μL)	Notch-1, NF-κB, VEGF	Induction of apoptosis and necrosis Induction of cell cycle arrest Increased radiosensitization of cancer cells	In vivo In vitro	Me180	[57]
	5× IC50 (34.23 μM/ml)	Wnt/β-catenin NF-κB pathway		In vitro	HeLa	[64]
	13 μM	BRCA1, p-p53, p-H2A.XSer140		In vitro	HeLa	[59]
	IC50= 16.52 μM	ROS, p21, Bax, p53, ROS, p21, Bax		In vitro	HeLa	[65]
	10 μM In vivo (4 mg/kg)	-		In vitro In vivo	HeLa	[66]
	10 μM	TGF-β activates Wnt/β-catenin signaling pathway		In vitro	SiHa HeLa	[67]
	10 μM	NF-κB-p53-caspase-3 pathway	Curcumin improves the paclitaxel-induced apoptosis of cervical cancer cell lines infected with HPV.	In vitro	CaSki HeLa	[68]
	5 μM	-	Curcumin-induced apoptosis and oxidative stress	In vitro	HeLa	[69]
	1000 and 1500 mg/kg for 30 days	-	Curcumin inhibits angiogenesis and tumor growth mediated by decreasing the expression of VEGF, EGFR, and COX-2.	In vivo	-	[62]
	50 μM	-	Curcumin sensitizes cervical cancer cells to cisplatin-based chemotherapy through inhibition of Pgp1and MRP1.	In vitro	SiHa SiHaR	[70]
	20 μM	-	Curcumin induced ER stress-mediated apoptosis via increasing of ROS generation and by activation of CHOP	In vitro	C33A CaSki HeLa ME180	[61]
	IC50: 17 μM (HeLa), 12 μM (ME-180), 51 μM (SiHa), 21 μM (SW756) Dose: 50 μM for 48h	-	Curcumin-based vaginal cream effectively eradicates HPV positive cervical cancer cells.	In vitro	HeLa ME-180 SiHa SW756	[71]
	10 and 25 μM	Akt, MAPK, and AP-1 pathways	Curcumin potentiates the antitumor effects of paclitaxel by downregulating Akt, MAPK, and AP-1 pathways and decreasing the transcription of NF-κB target genes.	In vivo	-	[72]
	25 and 50 μM	-	Curcumin can induce apoptosis by inhibition of PCNA, Cyclin D1, telomerase, and p16 and by activation of p53 and p73 in HPV-negative cancer cells pretreated with estradiol.	In vivo	HeLa SiHa CaSki C33A	[54]
	50 and 100 μM for 24h	Apoptosis and inflammatory pathways	Curcumin mediates apoptosis in SiHa and HeLa cell lines. Curcumin can act as an anti-proliferative and anti-inflammatory agent for Ca Ski, HeLa, and SiHa cells	In vitro	HeLa SiHa CaSki	[73]
	15 μM for 48h	-	Curcumin exhibits antitumor activity against cervical cancer cells. Curcumin downregulates PGE2 expression.	In vitro	HeLa	[56]
	10 μM for 8h	MAP kinase	Curcumin is a potent radiosensitizer	In vitro	HeLa	[74]

**Table 2** Conducted investigations on the treatment of cervical cancer with curcumin (*Continued*)

Type of curcumin	Dose	Main target (s)	Main effect (s)	Model (in vivo/ in vitro/human)	Cell line	Ref
		pathway	by increasing ROS production and overacts the MAP kinase pathway.		SiHa	
	10µM Combined curcumin (10µM) ultrasound (8 s of 5-7.5 MHz)	-	Curcumin can lead to necrosis in cervical cancer cell lines. Combined curcumin ultrasound enhances necrosis in cervical cancer cell lines.	In vitro	HeLa SiHa C33A	[60]
ST06-AgNPs	IC50: 1µM Dose: 1-2 µM Dose: 5 mg/kg body weight for 30 days (In vivo)	-	Inhibited cancer cell growth	In vivo In vitro	HeLa	[75]
Folic acid-modified liposomal curcumin	IC50: 1.47 µg/mL for free curcumin IC50: 0.45 µg/mL for (DSPE)-PEG2000-FA-LPs/CUR Dose: 25 mg/kg for 51 days (In vivo)	-	Anti-proliferative effects	In vitro In vivo	HeLa	[76]
4-Bromo-4'-chloro pyrazoline	IC <sub>50</sub> : 8.7µg/ml for Chloro bromo analog IC <sub>50</sub> : 42.24 µg/mL for curcumin	-	Apoptosis induction	In vitro	HeLa	[77]
Chloro and bromo-pyrazolecurcumin	IC50: 14.2 and 18.6 µg/ml for Chloro derivative and bromo analog, respectively. IC50: 42.4 µg/ml for curcumin	-	Apoptosis induction	In vitro	HeLa	[78]
Curcumin-loaded microbubble	1.25–40 µM	-	Decreased cancer cell viability	In vitro	HeLa	[79]
Bisdemethoxycurcumin	5µM for 24 and 48h	NF-κB, MMP-2 and -9 Pathways	Anti-migration and anti-invasion effects	In vitro	HeLa	[80]
Curcumin-PDT	-	Notch signaling pathway	Necrosis induction	In vivo	Me180	[81]
Curcumin-loaded micells	50 µg/mL	-	Increased cytotoxicity against cancer cells Apoptosis induction	In vitro	HeLa HepG2 NIH-3T3	[82]
Demethoxycurcumin	15 µM IC <sub>20</sub> : 7.5 µM	NF-κB Pathways	Anti-migration and anti-invasion effects	In vitro	HeLa	[83]
Curcumin-loaded chitosan nanoparticles	24µM	-	Apoptosis induction Anti-proliferative effects Showed better chemopreventive and chemotherapeutic effects than curcumin	In vitro	SiHa	[84]
Difluorinated curcumin Folate decorated bovine serum albumin (FA-BSA) nanoparticles loaded with Difluorinated curcumin (CDF) (FA-BSA-CDF)	Dose: 2 µM (Difluorinated curcumin and FA-BSA-CDF) Dose: 0.5 µM (Combination)	-	Synergistic anticancer effects Apoptosis induction	In vitro	HeLa SKOV3	[85]
Curcumin-nanoemulsion	20 to 40µM	-	Apoptosis induction	In vitro	CasKi SiHa HaCaT	[86]
Curcumin-Loaded TPGS/ F127/P123 Mixed Polymeric	Dose: 8 µg/mL Dose: 25 mg/kg for 11	-	Increased cytotoxicity against cancer cells Induction of apoptosis and cell	In vivo In vitro	HeLa NIH3T3	[87]

**Table 2** Conducted investigations on the treatment of cervical cancer with curcumin (*Continued*)

Type of curcumin	Dose	Main target (s)	Main effect (s)	Model (in vivo/ in vitro/human)	Cell line	Ref
Micelles	times in 2 days (In vivo)		cycle arrest		cells	
Curcumin-loaded chitosan-alginate-sodium tripolyphosphate nanoparticles	50 µg/mL	<i>Bax</i> , <i>Bcl-2</i>	Anti-proliferative effects Apoptosis induction	In vitro	HeLa	[88]
Folic acid conjugated polymeric micelles loaded with a curcumindifluorinated	0.47 ± 0.14 µM	PTEN, NF-κB	Apoptosis induction	In vitro	HeLa	[89]
Curcumin-loaded chitosan Nanoparticles	108 µM	<i>Bax</i> , <i>Bcl-2</i>	Apoptosis induction	In vitro	SiHa Hela Caski C33a	[90]
Tetrahydrocurcumin	100, 300, or 500 mg/kg body weight for 30 days	COX-2, EGFR, p-ERK1&2, p-AKT, Ki-67	Apoptosis induction Antitumor Effect	In vivo	CaSki	[91]
Nano-Curcumin	20 and 25 µM for 48h	Anti-survival pathways	Inhibited cancer cell growth Induction of apoptosis and cycle cell arrest	In vitro	SiHa, Caski	[19]
Tetrahydrocurcumin	50, 100 mg/kg	-	Inhibited cancer cell growth Anti-angiogenesis effects	In vivo In vitro	CaSki	[92, 93]
Curcumin (CCM)-loaded nanoscale zeolitic imidazolate framework-8 (CCM@NZIF-8) nanoparticles	Dose: 1-10 µg/mL Dose: 2.5 mg/kg body weight for 6 times in 2 days (In vivo)	-	Anti-proliferative effects Showed higher efficacy than free curcumin	In vivo In vitro	HeLa	[94]
Curcumin-loaded cationic liposome	IC <sub>50</sub> : 16, 21 µM	-	Apoptosis induction	In vitro	HeLa SiHa	[95]

increased apoptotic cell death induction [110]. They also stated that, because the mentioned combination are able to activate both the intrinsic and extrinsic apoptosis pathways, they may overcome chemoresistance to conventional chemotherapeutic drugs [110]. Epithelial ovarian cancer (EOC) spheroids have a key role in chemoresistance development [111]. A research was conducted to evaluate curcumin effects on chemoresistance and antiperitoneal metastasis in EOC spheroids [112]. It was indicated that high invasive EOC cells that form spheroids express a high level of aldehyde dehydrogenase 1 family member A1, a cancer stem cell marker, which was markedly downregulated by curcumin [112]. Curcumin significantly increased EOC spheroids' sensitivity to cisplatin and abolished their sphere-forming ability [112]. Furthermore, curcumin inhibited pre-existed EOC spheroids' growth and also suppressed their invasion to the mesothelial monolayers and their adhesion to extracellular matrix [112]. Table 3 summarizes the current data on the therapeutic effects of curcumin on ovarian cancer *in vivo* and *in vitro*.

**Limitation of curcumin**

The clinical anti-cancer effects of curcumin have not yet been fully documented despite its potential effects. Poor solubility in water is one of the main restrictions in

curcumin application (only about 11 ng / ml), thereby possibly limiting its beneficial effects [150]. Other drawbacks are instability in alkaline and neutral environments, and low bioavailability because of rapid metabolism and elimination [151, 152].

Intravenous, peritoneal and oral administration of curcumin leads to the formation of glucuronide metabolites in the liver and excretion through the bile into the gastrointestinal tract [153, 154]. In a study, daily administration of curcumin (3600 mg) in patients with metastatic colorectal cancer, the circulatory curcumin content was in nanomolar level [155]. Similarly, other findings showed minor changes in the peripheral blood of patients at high risk following daily administration of curcumin (8000 mg) [156]. After the administration of curcumin at the doses of 500-8000 mg, there was no measurable level in the blood and only a small amount of its metabolites was measured in research units taking 10,000-12,000 mg [157, 158]. It can be concluded that the therapeutic potentials of curcumin may be enhanced by improving its bioavailability and solubility.

**Novel formulations of curcumin in the treatment of gynecological cancers**

As mentioned before, curcumin has low absorption and poor bioavailability [159]; thus, several investigators have

**Table 3** Recent studies on curcumin treatment for ovarian cancer

Type of curcumin	Dose	Main target (s)	Main effect (s)	Model (in vivo/ in vitro/human)	Cell line	Ref
Curcumin	20 μM for 96 hours	Wnt/β-catenin	Inhibition of tumor growth, migration, and invasion	In vitro	SKOV3	[113]
	20 μM for 48 hours	-	Inhibition of epithelial-mesenchymal transition	In vitro	ES2, OVCAR3	[114]
	30, 40 μM for 48 hours	AKT/mTOR/p70S6K	Inhibition of autophagy	In vitro	SK-OV-3, A2780	[104]
	400 μM	NQO1, <i>c-Myc</i> , <i>Cyclin B1</i> , <i>Cyclin D1</i>	Induction of apoptosis Increased the sensitivity of cancer cells	In vitro	OVCAR3, OVCAR5, SKOV3	[115]
	20 μM	FAK	Induced cell cycle arrest Antioxidant and anti-proliferative effects	In vitro	SKOV-3, OVCAR-3, PA-1	[116]
	25.8, 53.0 mg/day	NF-κB		In vivo	-	[117]
	Dose: 20 mg/kg (In vivo) Dose: 10 μM for 48 hours	miR-124		In vitro In vivo	SKOV3	[118]
	1 μM for 36 hours	miR-214, MEG3		In vitro	A2780 OVCAR-3 SKOV3	[100]
	60 μM for 72 hours	-		In vitro	SKOV3	[119]
	50 μM	MMP-9, CD44, osteopontin		In vitro	SKOV3	[120]
	10 μM for 2 and 3 hours	STAT3, IL-6, IL-8		In vitro	PA-1, OVCAR-3	[121]
	80 μM for 24 hours	Caspase-3, PARP-1, Bcl-2, P13K/Akt, P38 MAPK		In vitro	HEY, OVCA429, OCC1, SKOV3	[22]
	50 μM for 240 min	Caspase-3, IL-6, STAT-3, p-JAK-1 and p-JAK-2, PIAS-3, SOCS-3		In vitro	OVCA420, OVCA429	[36]
	40 μM for 24 hours	AQP-3		In vitro	CaOV3	[108]
	0.5 μM for 48 hours	ROS, glutathione		In vitro	C13, 2008	[122]
	50μM for 24 hours	AMPK, p38, p53		In vitro	CaOV3	[123]
	40μM for 72 hours	PI3K/Akt		In vitro	SKOV3	[124]
	60μM	ALDH1A1		In vitro	SKOV3 OVCAR3	[112]
	15μM for 24 hours	SERCA		In vitro	MDAH 2774, SKOV3, PA1	[105]
	41.6μmol/L for 12 hours	Bcl-2, p53, MDM2, NFκB, caspase-3		In vitro	A2780	[125]
	3 μM for 12 hours	Rho A/Rho-kinase		In vitro	SKOV3	[126]
	40μM for 48 hours	Bcl-2, Bcl-xL, caspase-3, p53, Bax		In vitro	HO-8910	[106]
Curcumin-loaded biodegradable	0.1 mg/mL	-	CUR-NP exhibited better	In vitro	SK-OV-3	[127]



**Table 3** Recent studies on curcumin treatment for ovarian cancer (Continued)

Type of curcumin	Dose	Main target (s)	Main effect (s)	Model (in vivo/ in vitro/human)	Cell line	Ref
PLGA nanoparticles (CUR-NP)	50 $\mu$ M		physicochemical properties compared to free curcumin			
Curcumin-coated silver nanoparticles (cAgNPs)	2 $\mu$ g/mL for 48 hours	Caspase 3/9, p53, MPP-9	Apoptosis induction	In vitro	A2780	[128]
Combinational polymeric micelles for co-delivery of quercetin/resveratrol and resveratrol/curcumin	1 mg/ml	Caspase-3	Apoptosis induction	In vitro In vivo	ES2-Luc, A2780ADR	[129]
DNC	55 $\mu$ M for 48 hours	LSINCT5, CCAT2, ABO73614, ANRIL, FAL1, BC200, MALA T1	Apoptosis induction Inhibited tumor growth	In vitro	OVCAR3 SKOV3	[130]
Curcumin-loaded PLGA MPs	Dose: 20 and 40 $\mu$ M for 48 and 72 hours Dose: 100 mg/kg (In vivo)	-	CPMs formulation was more effective than free curcumin in suppressing proliferation of ovarian cancer cells	In vitro In vivo	SKOV-3	[131]
Curcumin nanoparticle	50 $\mu$ g/ml	<b>P-gp</b>	Decreased chemotherapy resistance Induced cell cycle arrest Apoptosis induction Antioxidant effects	In vitro In vitro In vivo	A2780 SKOV3	[132] [133]
	6.62 $\mu$ g/mL	HSP70				
Difluorinated curcumin Folate decorated bovine serum albumin (FA-BSA) nanoparticles loaded with Difluorinated curcumin (CDF) (FA-BSA-CDF)	162.8 nM	-	Apoptosis induction	In vitro	SKOV3	[85]
FA-SMA-CDF nanomicelles	1.55 $\pm$ 0.23 $\mu$ M for 72 hours	PTEN, NFkB,	Apoptosis induction	In vitro	SKOV3	[89]
Demethoxycurcumin	20, 40 and 80 $\mu$ M for 48 hours	IRS2/PI3K/Akt miR-551a	Anti-proliferative effects Apoptosis induction	In vitro	ES2, HO8640, HO8640PM, SKOV3	[134]
Doxorubicin/curcumin co-loaded alginate-shelled nanodroplets	-	-	Inhibited tumor growth	In vitro In vivo	A2780	[135]
Boron-curcumin complex	6 mg	-	Enhancement of anticancer effects of curcumin	In vitro	IGROV-1	[136]
Curcumin-loaded NLC Curcumin	30 $\mu$ M for 24 hours	PARP, caspase-3	Apoptosis induction	In vitro	A2780	[137]
Curcumin-loaded $\delta$ -T3 nanoemulsion	1.96 $\pm$ 0.37 mg/ml	NF- $\kappa$ B	Anti-proliferative effects Apoptosis induction	In vitro	OVCAR-8	[138]
Bisdemethoxycurcumin	15 $\mu$ M for 24 hours	MMP-2, -9 CD147, uPA, ICAM-1, VCAM-1, TIMP-1, NF- $\kappa$ B p65, VEGF	Inhibited growth, adhesion and motility of tumor cells Arrested cell cycle Anti-migration and anti-invasion effects Antioxidant effects	In vitro	SKOV-3	[139]
Monofunctional platinum (II) tris (quinoline) chloroplatinum (II)	60 to 200 $\mu$ M for 72 hours	-	Greater toxicity on resistant tumor cells compared to cisplatin	In vitro	A2780	[140]
ASA/Cur-coloaded mPEG-PLGA nanoparticles	5 $\mu$ g/mL	Caspase-3, -9 Bcl-2, Bax	Apoptosis induction The co-delivery of curcumin enhanced its antitumor activity	In vitro	ES-2, SKOV3	[141]
Curcumin and platinum-loaded micelles	1 mg	-	The co-delivery of curcumin enhanced its antitumor activity	In vitro	A2780	[142]
MPEG-PCL curcumin micelles	5 $\mu$ g/mL	-	Induced cell cycle arrest and	In vitro	A2780	[143]

**Table 3** Recent studies on curcumin treatment for ovarian cancer (Continued)

Type of curcumin	Dose	Main target (s)	Main effect (s)	Model (in vivo/ in vitro/human)	Cell line	Ref
Monofunctional platinum (II) complex <i>tris</i> (benzimidazole) chloroplatinum (II)	180 mg	-	apoptosis Synergistic anticancer effects on cisplatin-resistant cancer cells	In vitro	A2780	[144]
Co-delivery of paclitaxel and curcumin by transferrin-targeted PEG-PE-based mixed micelles	20 μM 25 mg/kg	Annexin V	Apoptosis induction	In vitro In vivo	NCI-ADR-RES SK-OV-3	[145]
PEG-PE/vitamin E micelles for co-delivery of paclitaxel and curcumin	10 μM 25 mg/kg	-	Showed synergistic effects compared to curcumin or paclitaxel alone against cancer cells	In vitro In vivo	SK-OV-3	[146]
Curcumin loaded poly(2-hydroxyethyl methacrylate) nanoparticles	10 μg/ml	NFκB, survivin, VEGF, COX-2	Anti-proliferative effects Necrosis induction	In vitro	SK-OV-3	[147]
*B19 (1E, 4E)-1, 5-bis (2-methoxyphenyl) penta-1, 4-dien-3-one	10 μM for 12 hours	ER stress, UPR	Inhibited autophagy Apoptosis induction	In vitro	HO8910	[148]
Curcumin encapsulated Poloxamer 407/TPGS mixed micelles	-	P-gp	Increased cytotoxicity against multidrug resistant ovarian cancer cells	In vitro	NCI/ADR-RES	[149]

been attempting to improve its therapeutic effectiveness and pharmacokinetic profile by approaches such as development of new analogs [150, 160, 161]. Structural alterations in curcumin molecule leads to numerous beneficial properties for treating different diseases, including neurodegenerative diseases, diabetes, and cardiovascular diseases [159]. Curcumin and its analogs are extensively utilized as antioxidants, antimicrobial, anti-inflammatory, and anticancer agents. Successful attempts for synthesizing new analogues of curcumin with enhanced bioactivity have been reported [3, 162, 163]. It has been indicated that curcumin has anticancer functions due to its impact on various biological pathways implicated in metastasis, apoptosis, cell cycle regulation, tumorigenesis, oncogene expression, and mutagenesis [164, 165]. Recently, it has been revealed that some of these analogs display considerably stronger anticancer property than curcumin [50–53]. Hence, to overcome the restrictions of curcumin, researchers are developing and evaluating increasing number of curcumin novel analogs [166–168]. These analogs have shown a wide-spectrum of anticancer features in different cancer cells, such as colon [169], breast [170], and prostate [171].

Pan and colleagues indicated that, in plasma of curcumin-treated animals, 99% of the administered curcumin is glucuronide-conjugated [172]. It was also revealed that reduced curcumin metabolites, including curcumin glucuronosides, dihydrocurcumin and tetrahydrocurcumin are the main curcumin metabolites [172]. It has been shown that these metabolites have a crucial role in multiple therapeutic effects, including anticancer [173], anti-inflammation [174], and antioxidation [175]. However, numerous investigation have demonstrated

that anticancer activity of curcumin metabolites is weaker in comparison to the parent molecule [176, 177]. Thus, several approaches, such as structural modification and improvising carrier molecules have been tested to compensate the curcumin's bioavailability limitations [176]. For increasing the therapeutic potential and bioavailability, different delivery systems including phospholipid complexes, micelles, nanoparticles, and liposomes have been recently recommended for curcumin treatment in cancer [176]. For instance, phospholipid complexes and micelles improve curcumin's gastrointestinal absorption, leading to greater plasma concentrations [176]. It has been revealed that curcumin-loaded amphiphilic mixed micelles has better bioavailability, causes remarkable accumulation of rhodamine, and modulates the expression levels of IL-6, IL-10 and TNF-α [41]. It also induced apoptosis and enhanced the intracellular uptake leading to inhibition of Ishikawa EC cells' growth [41]. Xu et al. conducted a research to evaluate the efficacy of liposomal curcumin as a treatment for endometrial cancer [178]. Liposomal curcumin dose-dependently suppressed the motility, induced apoptosis and inhibited the proliferation of HEC-1 and Ishikawa cells [178]. It also blocked the expression of MMP-9, caspase-3, and NF-κB. Importantly, no toxicity was seen in the zebrafish model [178]. Demethoxycurcumin, a novel derivative of curcumin, induced apoptosis in cervical cancer cells *in vitro* and decreased tumor volume in an *in vivo* model [91]. In an investigation, curcumin-loaded chitosan nanoparticles were used for cervical cancer cells and it was shown that this delivery system enhanced the anti-proliferative effects of the drug against cancer cells and was not toxic to normal cells

[90]. Du et al. reported that demethoxycurcumin, a curcumin analog, inhibited insulin receptor substrate-2 (IRS2) through miR-551a upregulation leading to hindering of ovarian cancer cells growth [134]. Compared to free curcumin, curcumin-loaded nanostructured lipid carriers (NLCs) showed better anticancer results, and more effectively reduced cell colony survival. These findings suggest that the curcumin entrapment into NLCs enhances the efficacy of curcumin *in vitro* [137]. Hosseini et al. have recently demonstrated that dendrosomal nanocurcumin (DNC) leads to greater cell death when combined with oxaliplatin. DNC also induced apoptosis in ovarian cancer cells [179]. De Matos et al. indicated that curcumin-nanoemulsion acts as a photosensitizing agent in PDT, demonstrating potential alternative capacity for cervical lesions [86]. Making novel formulations such as effective derivatives, as well as utilizing novel drug delivery systems can significantly increase the anti-cancer potential of curcumin. More experimental studies and human trials are needed to confirm the efficacy of curcumin and its novel formulations for the treatment of gynecological cancers.

### Conclusion and future perspectives

Gynecologic cancers represent a wide variety of cancers such as ovarian, uterine/endometrial, cervical, gestational trophoblastic, primary peritoneal, vaginal and vulvar cancers. Some of these cancers are known as “silent killer”, since the patient is usually unaware of tumor presence, until it is too late to cure. On the other hand, current therapeutic approaches carry serious limitations. Hence, developing new therapeutic platforms could optimize the treatment outcome for these cancers.

Curcumin is a well-known natural compound, which possesses a wide range of biologic effects such as anti-inflammatory, anti-cancer, and anti-oxidant activities. Several studies have proved the potential benefit of curcumin treatment both with monotherapy and in combination with standard chemotherapy drugs. The anti-cancer effects of curcumin in gynecologic cancers is shown to be linked to activation of autophagic and apoptotic pathways and inhibition of invasion and metastasis in various tumors. Curcumin suppresses major regulatory genes such as NF- $\kappa$ B and its downstream gene targets, which play significant roles in controlling invasion and metastasis of cancer cells. Interestingly, curcumin has been shown to improve the efficacy of current therapies by sensitizing resistance cancer cells to chemoradiotherapy, which has been a big obstacle in cancer treatment. Importantly, the safety and well-tolerability of curcumin has been demonstrated in clinical trials.

Along with different beneficial effects, curcumin treatment faces some limitations such as low *bioavailability*.

However, several studies have proposed new formulations of curcumin to overcome this problem. Also utilization of different analogues and novel delivery systems such as nanoparticles, liposomes and micelles may further improve the anti-cancer effects of curcumin and open a new horizon in the treatment of gynecologic cancers.

### Acknowledgements

Not applicable.

### Authors' contributions

HM involved in conception, design, statistical analysis and drafting of the manuscript. MD, MH-P, RM, MR, JT, MJ, MJA and AS contributed in data collection and manuscript drafting. All authors approved the final version for submission.

### Funding

Not applicable.

### Ethics approval and consent to participate

Not applicable.

### Consent for publication

Not applicable.

### Competing interests

The authors have no conflict of interest to disclose.

### Author details

<sup>1</sup>Halal Research Center of IRI, FDA, Tehran, Iran. <sup>2</sup>Department of Medical Biotechnology, Faculty of Medicine, Arak University of Medical Science, Arak, Iran. <sup>3</sup>Faculty of Member, Ardestan Branch, Islamic Azad University, Ardestan, Iran. <sup>4</sup>Department of Oral and Maxillofacial Surgery, Kashan University of Medical Sciences, Kashan, Iran. <sup>5</sup>Trauma Research Center, Kashan University of Medical Sciences, Kashan, Iran. <sup>6</sup>Clinical Research Development Center (CRDC), Sayad Shirazi Hospital, Golestan University of Medical Sciences, Gorgan, Iran. <sup>7</sup>Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. <sup>8</sup>School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. <sup>9</sup>Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran.

Received: 28 January 2020 Accepted: 23 October 2020

Published online: 04 November 2020

### References

- Li Y, Kong D, Wang Z, Sarkar FH. Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. *Pharm Res*. 2010;27(6):1027–41.
- Reuter S, Gupta SC, Park B, Goel A, Aggarwal BB. Epigenetic changes induced by curcumin and other natural compounds. *Genes Nutr*. 2011;6(2):93–108.
- Vallianou NG, Evangelopoulos A, Schizas N, Kazazis C. Potential anticancer properties and mechanisms of action of curcumin. *Anticancer Res*. 2015;35(2):645–51.
- Teymouri M, Pirro M, Johnston TP, Sahebkar A. Curcumin as a multifaceted compound against human papilloma virus infection and cervical cancers: A review of chemistry, cellular, molecular, and preclinical features. *BioFactors*. 2017;43(3):331–46.
- Miriyala S, Panchatcharam M, Rengarajulu P. Cardioprotective effects of curcumin. *Adv Exp Med Biol*. 2007;595:359–77.
- Um MY, Hwang KH, Choi WH, Ahn J, Jung CH, Ha TY. Curcumin attenuates adhesion molecules and matrix metalloproteinase expression in hypercholesterolemic rabbits. *Nutr Res (New York, NY)*. 2014;34(10):886–93.
- Moghadamtousi SZ, Kadir HA, Hassandarvish P, Tajik H, Abubakar S, Zandi K. A review on antibacterial, antiviral, and antifungal activity of curcumin. *BioMed Res Int*. 2014;2014:186864.

8. Sahebkar A, Serban M-C, Ursoniu S, Banach M. Effect of curcuminoids on oxidative stress: A systematic review and meta-analysis of randomized controlled trials. *J Functional Foods*. 2015;18:898–909.
9. Panahi Y, Hosseini MS, Khalili N, Naimi E, Simental-Mendia LE, Majeed M, Sahebkar A. Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: A post-hoc analysis of a randomized controlled trial. *Biomed Pharmacother*. 2016;82:578–82.
10. Abdollahi E, Momtazi AA, Johnston TP, Sahebkar A. Therapeutic effects of curcumin in inflammatory and immune-mediated diseases: A nature-made jack-of-all-trades? *J Cell Physiol*. 2018;233(2):830–48.
11. Mollazadeh H, Cicero AFG, Blesso CN, Pirro M, Majeed M, Sahebkar A. Immune modulation by curcumin: The role of interleukin-10. *Crit Rev Food Sci Nutr*. 2019;59(1):89–101.
12. Momtazi AA, Derosa G, Maffioli P, Banach M, Sahebkar A. Role of microRNAs in the Therapeutic Effects of Curcumin in Non-Cancer Diseases. *Mol Diagn Ther*. 2016;20(4):335–45.
13. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. *AAPS J*. 2013;15(1):195–218.
14. Soleimani V, Sahebkar A, Hosseinzadeh H. Turmeric (*Curcuma longa*) and its major constituent (curcumin) as nontoxic and safe substances: Review. *Phytother Res*. 2018;32(6):985–95.
15. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. *Int J Cancer*. 2019;144(8):1941–53.
16. Suh DH, Kim M, Lee KH, Eom KY, Kjeldsen MK, Mirza MR, Kim JW. Major clinical research advances in gynecologic cancer in 2017. *J Gynecol Oncol*. 2018;29(2):e31.
17. Kumar G, Mittal S, Sak K, Tuli HS. Molecular mechanisms underlying chemopreventive potential of curcumin: Current challenges and future perspectives. *Life Sci*. 2016;148:313–28.
18. Shepherd JH. Revised FIGO staging for gynaecological cancer. *Br J Obstet Gynaecol*. 1989;96(8):889–92.
19. Zaman MS, Chauhan N, Yallapu MM, Gara RK, Maher DM, Kumari S, Sikander M, Khan S, Zafar N, Jaggi M, et al. Curcumin Nanoformulation for Cervical Cancer Treatment. *Sci Rep*. 2016;6:20051.
20. Maruthur NM, Bolen SD, Brancati FL, Clark JM. The association of obesity and cervical cancer screening: a systematic review and meta-analysis. *Obesity (Silver Spring, Md)*. 2009;17(2):375–81.
21. Chen Q, Gao Q, Chen K, Wang Y, Chen L, Li XU. Curcumin suppresses migration and invasion of human endometrial carcinoma cells. *Oncol Lett*. 2015;10(3):1297–302.
22. Watson JL, Greenshields A, Hill R, Hilchie A, Lee PW, Giacomantonio CA, Hoskin DW. Curcumin-induced apoptosis in ovarian carcinoma cells is p53-independent and involves p38 mitogen-activated protein kinase activation and downregulation of Bcl-2 and survivin expression and Akt signaling. *Mol Carcinog*. 2010;49(1):13–24.
23. Momtazi-Borojeni AA, Mosafer J, Nikfar B, Ekhlasi-Hundrieser M, Chaichian S, Mehdizadehkashi A, Vaezi A. Curcumin in Advancing Treatment for Gynecological Cancers with Developed Drug- and Radiotherapy-Associated Resistance. *Rev Physiol Biochem Pharmacol*. 2019;176:107–29.
24. Kajo K, Vallova M, Biro C, Bognar G, Machalekova K, Zavodna K, Galbavy S, Zubor P. Molecular pathology of endometrial carcinoma - a review. *Cesk Patol*. 2015;51(2):65–73.
25. Buhtoiarova TN, Brenner CA, Singh M. Endometrial Carcinoma: Role of Current and Emerging Biomarkers in Resolving Persistent Clinical Dilemmas. *Am J Clin Pathol*. 2016;145(1):8–21.
26. Chen S, Sun KX, Liu BL, Zong ZH, Zhao Y. The role of glycogen synthase kinase-3beta (GSK-3beta) in endometrial carcinoma: A carcinogenesis, progression, prognosis, and target therapy marker. *Oncotarget*. 2016;7(19):27538–51.
27. Yeramian A, Garcia V, Bergada L, Domingo M, Santacana M, Valls J, Martinez-Alonso M, Carceller JA, Cussac AL, Dolcet X, et al. Bioluminescence Imaging to Monitor the Effects of the Hsp90 Inhibitor NVP-AUY922 on NF-kappaB Pathway in Endometrial Cancer. *Mol Imaging Biol*. 2016;18(4):545–56.
28. Fuso L, Evangelista A, Pagano E, Piovano E, Perotto S, Mazzola S, Bertoldo E, La Porta MR, Rosmino C, Furbatto G, et al. Variation in gynecological oncology follow-up practice: attributable to cancer centers or to patient characteristics? A Piedmont Regional Oncology Network Study. *Tumori*. 2011;97(5):551–8.
29. Duong LM, Wilson RJ, Ajani UA, Singh SD, Ehemann CR. Trends in endometrial cancer incidence rates in the United States, 1999–2006. *J Women's Health (2002)*. 2011;20(8):1157–63.
30. Dewdney SB, Kizer NT, Andaya AA, Babb SA, Luo J, Mutch DG, Schmidt AP, Brinton LA, Broaddus RR, Ramirez NC, et al. Uterine serous carcinoma: increased familial risk for lynch-associated malignancies. *Cancer Prev Res (Philadelphia, Pa)*. 2012;5(3):435–43.
31. Ueda SM, Kapp DS, Cheung MK, Shin JY, Osann K, Husain A, Teng NN, Berek JS, Chan JK. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. *Am J Obstet Gynecol*. 2008;198(2):218.e211–6.
32. Sirohi VK, Popli P, Sankhwar P, Kaushal JB, Gupta K, Manohar M, Dwivedi A. Curcumin exhibits anti-tumor effect and attenuates cellular migration via Slit-2 mediated down-regulation of SDF-1 and CXCR4 in endometrial adenocarcinoma cells. *J Nutr Biochem*. 2017;44:60–70.
33. Davey RA, Grossmann M. Androgen Receptor Structure, Function and Biology: From Bench to Bedside. *Clin Biochem Rev*. 2016;37(1):3–15.
34. Feng W, Yang CX, Zhang L, Fang Y, Yan M. Curcumin promotes the apoptosis of human endometrial carcinoma cells by downregulating the expression of androgen receptor through Wnt signal pathway. *Eur J Gynaecol Oncol*. 2014;35(6):718–23.
35. Sun MX, Yu F, Gong ML, Fan GL, Liu CX. Effects of curcumin on the role of MMP-2 in endometrial cancer cell proliferation and invasion. *Eur Rev Med Pharmacol Sci*. 2018;22(15):5033–41.
36. Saydmohammed M, Joseph D, Syed V. Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells. *J Cell Biochem*. 2010a; 110(2):447–56.
37. Patel SK, Jackson L, Warren AY, Arya P, Shaw RW, Khan RN. A role for two-pore potassium (K2P) channels in endometrial epithelial function. *J Cell Mol Med*. 2013;17(1):134–46.
38. Liang Y-J, Zhang H-M, Wu Y-Z, Hao Q, Wang J-D, Hu Y-L. Inhibiting effect of letrozole combined with curcumin on xenografted endometrial carcinoma growth in nude mice. *Chin J Cancer*. 2010;29(1):9–14.
39. Yu Z, Shah DM. Curcumin down-regulates Ets-1 and Bcl-2 expression in human endometrial carcinoma HEC-1-A cells. *Gynecol Oncol*. 2007;106(3):541–8.
40. Pereira MC, Mohammed R, VAN Otterloo WAL, DE Koning CB, Davids H. Evaluation of the Effects of Aminonaphthoquinone Derivatives in Combination with Curcumin Against ER-positive Breast Cancer and Related Tumours. *Anticancer Res*. 2017;37(12):6749–59.
41. Kumar A, Sirohi VK, Anum F, Singh PK, Gupta K, Gupta D, Saraf SA, Dwivedi A, Chourasia MK. Enhanced apoptosis, survivin down-regulation and assisted immunochemotherapy by curcumin loaded amphiphilic mixed micelles for subjugating endometrial cancer. *Nanomedicine*. 2017;13(6): 1953–63.
42. Xu H, Gong Z, Zhou S, Yang S, Wang D, Chen X, Wu J, Liu L, Zhong S, Zhao J, et al. Liposomal Curcumin Targeting Endometrial Cancer Through the NF-kappaB Pathway. *Cell Physiol Biochem*. 2018;48(2):569–82.
43. Tuytaerts S, Rombauts K, Everaert T, Van Nuffel AMT, Amant F. A Phase 2 Study to Assess the Immunomodulatory Capacity of a Lecithin-based Delivery System of Curcumin in Endometrial Cancer. *Front Nutr*. 2018;5:138.
44. Wu ES, Jeronimo J, Feldman S. Barriers and Challenges to Treatment Alternatives for Early-Stage Cervical Cancer in Lower-Resource Settings. *J Global Oncol*. 2017;3(5):572–82.
45. Kessler TA. Cervical Cancer: Prevention and Early Detection. *Semin Oncol Nurs*. 2017;33(2):172–83.
46. Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2017;28(suppl\_4):iv72–83.
47. LaVigne AW, Tiedman SA, Randall TC, Trimble EL, Viswanathan AN. Cervical cancer in low and middle income countries: Addressing barriers to radiotherapy delivery. *Gynecol Oncol Rep*. 2017;22:16–20.
48. Horner M, Ries L, Krapcho M, Neyman N, Aminou R, Howlander N, Altekruse S, Feuer E, Huang L, Mariotto A. SEER Cancer Statistics Review, 1975–2013, vol. 19. Bethesda: National Cancer Institute; 2013.
49. zur Hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. *Virology*. 2009;384(2):260–5.
50. Maher DM, Bell MC, O'Donnell EA, Gupta BK, Jaggi M, Chauhan SC. Curcumin suppresses human papillomavirus oncoproteins, restores p53, Rb, and PTPN13 proteins and inhibits benzo [a]pyrene-induced upregulation of HPV E7. *Mol Carcinog*. 2011;50(1):47–57.
51. Moore EE, Wark JD, Hopper JL, Erbas B, Garland SM. The roles of genetic and environmental factors on risk of cervical cancer: a review of classical twin studies. *Twin Res Hum Genet*. 2012;15(1):79–86.

52. Nardo L, Andreoni A, Bondani M, Masson M, Hjorth Tonnesen H. Studies on curcumin and curcuminoids. XXXIV. Photophysical properties of a symmetrical, non-substituted curcumin analogue. *J Photochem Photobiol B*. 2009;97(2):77–86.
53. Prusty BK, Das BC. Constitutive activation of transcription factor AP-1 in cervical cancer and suppression of human papillomavirus (HPV) transcription and AP-1 activity in HeLa cells by curcumin. *Int J Cancer*. 2005;113(6):951–60.
54. Singh M, Singh N. Curcumin counteracts the proliferative effect of estradiol and induces apoptosis in cervical cancer cells. *Mol Cell Biochem*. 2011;347(1–2):1–11.
55. Di Domenico F, Foppoli C, Coccia R, Perluigi M. Antioxidants in cervical cancer: chemopreventive and chemotherapeutic effects of polyphenols. *Biochim Biophys Acta*. 2012;1822(5):737–47.
56. Madden K, Flowers L, Salani R, Horowitz I, Logan S, Kowalski K, Xie J, Mohammed SI. Proteomics-based approach to elucidate the mechanism of antitumor effect of curcumin in cervical cancer. *Prostaglandins Leukot Essent Fatty Acids*. 2009;80(1):9–18.
57. He G, Mu T, Yuan Y, Yang W, Zhang Y, Chen Q, Bian M, Pan Y, Xiang Q, Chen Z, et al. Effects of Notch Signaling Pathway in Cervical Cancer by Curcumin Mediated Photodynamic Therapy and Its Possible Mechanisms in Vitro and in Vivo. *J Cancer*. 2019;10(17):4114–22.
58. Ghasemi F, Shafiee M, Banikazemi Z, Pourhanifeh MH, Khanbabaei H, Shamshirian A, Moghadam SA, ArefNezhad R, Sahebkar A, Avan A. Curcumin inhibits NF- $\kappa$ B and Wnt/ $\beta$ -catenin pathways in cervical cancer cells. *Pathol Res Pract*. 2019;215(10):152556.
59. Shang H-S, Chang C-H, Chou Y-R, Yeh M-Y, Au M-K, Lu H-F, Chu Y-L, Chou H-M, Chou H-C, Shih Y-L. Curcumin causes DNA damage and affects associated protein expression in HeLa human cervical cancer cells. *Oncol Rep*. 2016;36(4):2207–15.
60. Carr KR, Ioffe YJ, Filippova M, Duerksen-Hughes P, Chan PJ. Combined ultrasound-curcumin treatment of human cervical cancer cells. *Eur J Obstet Gynecol Reprod Biol*. 2015;193:96–101.
61. Kim B, Kim HS, Jung EJ, Lee JY, Tsang BK, Lim JM, Song YS. Curcumin induces ER stress-mediated apoptosis through selective generation of reactive oxygen species in cervical cancer cells. *Mol Carcinog*. 2016;55(5):918–28.
62. Yoysungnoen-Chintana P, Bhattarakosol P, Patumraj S. Antitumor and antiangiogenic activities of curcumin in cervical cancer xenografts in nude mice. *Biomed Res Int*. 2014;2014:817972.
63. Aedo-Aguilera V, Carrillo-Beltran D, Calaf GM, Munoz JP, Guerrero N, Osorio JC, Tapia JC, Leon O, Contreras HR, Aguayo F. Curcumin decreases epithelialmesenchymal transition by a Pirindependent mechanism in cervical cancer cells. *Oncol Rep*. 2019;42(5):2139–48.
64. Ghasemi F, Shafiee M, Banikazemi Z, Pourhanifeh MH, Khanbabaei H, Shamshirian A, Amiri Moghadam S, ArefNezhad R, Sahebkar A, Avan A, et al. Curcumin inhibits NF- $\kappa$ B and Wnt/ $\beta$ -catenin pathways in cervical cancer cells. *Pathol Res Pract*. 2019;215(10):152556.
65. Kumar D, Basu S, Parija L, Rout D, Manna S, Dandapat J, Debata PR. Curcumin and Ellagic acid synergistically induce ROS generation, DNA damage, p53 accumulation and apoptosis in HeLa cervical carcinoma cells. *Biomed Pharmacother*. 2016;81:31–7.
66. Lee JW, Park S, Kim SY, Um SH, Moon EY. Curcumin hampers the antitumor effect of vinblastine via the inhibition of microtubule dynamics and mitochondrial membrane potential in HeLa cervical cancer cells. *Phytomedicine*. 2016;23(7):705–13.
67. Thacker PC, Karunakaran D. Curcumin and emodin down-regulate TGF- $\beta$  signaling pathway in human cervical cancer cells. *PLoS one*. 2015;10(3):e0120045.
68. Dang YP, Yuan XY, Tian R, Li DG, Liu W. Curcumin improves the paclitaxel-induced apoptosis of HPV-positive human cervical cancer cells via the NF- $\kappa$ B-p53-caspase-3 pathway. *Exp Ther Med*. 2015;9(4):1470–6.
69. Lewinska A, Adamczyk J, Pajak J, Stoklosa S, Kubis B, Pastuszek P, Slota E, Wnuk M. Curcumin-mediated decrease in the expression of nucleolar organizer regions in cervical cancer (HeLa) cells. *Mutat Res Genet Toxicol Environ Mutagen*. 2014;771:43–52.
70. Roy M, Mukherjee S. Reversal of resistance towards cisplatin by curcumin in cervical cancer cells. *Asian Pac J Cancer Prev*. 2014;15(3):1403–10.
71. Debata PR, Castellanos MR, Fata JE, Baggett S, Rajupet S, Szerszen A, Begum S, Mata A, Murty W, Opitz LM, et al. A novel curcumin-based vaginal cream Vacurin selectively eliminates apposed human cervical cancer cells. *Gynecol Oncol*. 2013;129(1):145–53.
72. Sreekanth CN, Bava SV, Sreekumar E, Anto RJ. Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer. *Oncogene*. 2011;30(28):3139–52.
73. Singh M, Singh N. Molecular mechanism of curcumin induced cytotoxicity in human cervical carcinoma cells. *Mol Cell Biochem*. 2009;325(1–2):107–19.
74. Jawadi P, Segan AT, Tuttle SW, Koumenis C. The chemopreventive agent curcumin is a potent radiosensitizer of human cervical tumor cells via increased reactive oxygen species production and overactivation of the mitogen-activated protein kinase pathway. *Mol Pharmacol*. 2008;73(5):1491–501.
75. Murugesan K, Koroth J, Srinivasan PP, Singh A, Mukundan S, Karki SS, Choudhary B, Gupta CM. Effects of green synthesised silver nanoparticles (ST06-AgNPs) using curcumin derivative (ST06) on human cervical cancer cells (HeLa) in vitro and EAC tumor bearing mice models. *Int J Nanomedicine*. 2019;14:5257–70.
76. Wang WY, Cao YX, Zhou X, Wei B. Delivery of folic acid-modified liposomal curcumin for targeted cervical carcinoma therapy. *Drug Des Devel Ther*. 2019;13:2205–13.
77. Chaudhary M, Kumar N, Baldi A, Chandra R, Babu MA, Madan J. 4-Bromo-4'-chloro pyrazoline analog of curcumin augmented anticancer activity against human cervical cancer, HeLa cells: in silico-guided analysis, synthesis, and in vitro cytotoxicity. *J Biomol Struct Dyn*. 2020;38(5):1335–53.
78. Chaudhary M, Kumar N, Baldi A, Chandra R, Arockia Babu M, Madan J. Chloro and bromo-pyrazole curcumin Knoevenagel condensates augmented anticancer activity against human cervical cancer cells: design, synthesis, in silico docking and in vitro cytotoxicity analysis. *J Biomol Struct Dyn*. 2020;38(1):200–18.
79. Upadhyay A, Yagnik B, Desai P, Dalvi SV. Microbubble-Mediated Enhanced Delivery of Curcumin to Cervical Cancer Cells. *ACS omega*. 2018;3(10):12824–31.
80. Liao CL, Chu YL, Lin HY, Chen CY, Hsu MJ, Liu KC, Lai KC, Huang AC, Chung JG. Bisdemethoxycurcumin Suppresses Migration and Invasion of Human Cervical Cancer HeLa Cells via Inhibition of NF- $\kappa$ B, MMP-2 and -9 Pathways. *Anticancer Res*. 2018;38(7):3989–97.
81. He GF, Mu TL, Pan YS, Chen ZH, Xiang Q, Yang WY, Zhang Y, Yuan YL, Sun AP. Inhibitory effect of DAPT on Notch signaling pathway in curcumin mediated photodynamic therapy for cervical cancer xenografts in nude mice. *Zhonghua Yi Xue Za Zhi*. 2018;98(19):1511–6.
82. Kumari P, Rompicharla SVK, Muddineti OS, Ghosh B, Biswas S. Transferrin-anchored poly (lactide) based micelles to improve anticancer activity of curcumin in hepatic and cervical cancer cell monolayers and 3D spheroids. *Int J Biolog Macromol*. 2018;116:1196–213.
83. Lin CC, Kuo CL, Huang YP, Chen CY, Hsu MJ, Chu YL, Chueh FS, Chung JG. Demethoxycurcumin Suppresses Migration and Invasion of Human Cervical Cancer HeLa Cells via Inhibition of NF- $\kappa$ B Pathways. *Anticancer Res*. 2018;38(5):2761–9.
84. Khan MA, Zafaryab M, Mehdi SH, Ahmad I, Rizvi MMA. Physicochemical Characterization of Curcumin Loaded Chitosan Nanoparticles: Implications in Cervical Cancer. *Anti-cancer Agents Med Chem*. 2018;18(8):1131–7.
85. Gawde KA, Sau S, Tatiparti K, Kashaw SK, Mehrmohammadi M, Azmi AS, Iyer AK. Paclitaxel and di-fluorinated curcumin loaded in albumin nanoparticles for targeted synergistic combination therapy of ovarian and cervical cancers. *Colloids Surf B, Biointerfaces*. 2018;167:8–19.
86. de Matos RPA, Calmon MF, Amantino CF, Villa LL, Primo FL, Tedesco AC, Rahal P. Effect of Curcumin-Nanoemulsion Associated with Photodynamic Therapy in Cervical Carcinoma Cell Lines. *Biomed Res Int*. 2018;2018:4057959.
87. Wang J, Liu Q, Yang L, Xia X, Zhu R, Chen S, Wang M, Cheng L, Wu X, Wang S. Curcumin-Loaded TPGS/F127/P123 Mixed Polymeric Micelles for Cervical Cancer Therapy: Formulation, Characterization, and InVivo and InVivo Evaluation. *J Biomed Nanotechnol*. 2017;13(12):1631–46.
88. Ahmadi F, Ghasemi-Kasman M, Ghasemi S, Gholamitabar Tabari M, Pourbagher R, Kazemi S, Alinejad-Mir A. Induction of apoptosis in HeLa cancer cells by an ultrasonic-mediated synthesis of curcumin-loaded chitosan-alginate-STPP nanoparticles. *Int J Nanomedicine*. 2017;12:8545–56.
89. Luong D, Kesharwani P, Alsaab HO, Sau S, Padhye S, Sarkar FH, Iyer AK. Folic acid conjugated polymeric micelles loaded with a curcumin difluorinated analog for targeting cervical and ovarian cancers. *Colloids Surf B Biointerfaces*. 2017;157:490–502.
90. Khan MA, Zafaryab M, Mehdi SH, Ahmad I, Rizvi MM. Characterization and anti-proliferative activity of curcumin loaded chitosan nanoparticles in cervical cancer. *Int J Biolog Macromol*. 2016;93(Pt A):242–53.

91. Yoosungnoen B, Bhattarakosol P, Changtam C, Patumraj S. Effects of Tetrahydrocurcumin on Tumor Growth and Cellular Signaling in Cervical Cancer Xenografts in Nude Mice. *Biomed Res Int.* 2016;2016:1781208.
92. Yoosungnoen B, Bhattarakosol O, Changtam C, Patumraj S. Combinational Treatment Effect of Tetrahydrocurcumin and Celecoxib on Cervical Cancer Cell-Induced Tumor Growth and Tumor Angiogenesis in Nude Mice. *J Med Assoc Thai.* 2016;99(Suppl 4):S23–31.
93. Yoosungnoen B, Bhattarakosol P, Patumraj S, Changtam C. Effects of tetrahydrocurcumin on hypoxia-inducible factor-1 $\alpha$  and vascular endothelial growth factor expression in cervical cancer cell-induced angiogenesis in nude mice. *Biomed Res Int.* 2015;2015:391748.
94. Zheng M, Liu S, Guan X, Xie Z. One-Step Synthesis of Nanoscale Zeolitic Imidazolate Frameworks with High Curcumin Loading for Treatment of Cervical Cancer. *ACS Appl Mater Interfaces.* 2015;7(40):22181–7.
95. Saengkrit N, Saesoo S, Srinuanchai W, Phunpee S, Ruktanonchai UR. Influence of curcumin-loaded cationic liposome on anticancer activity for cervical cancer therapy. *Colloids Surf B Biointerfaces.* 2014;114:349–56.
96. Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline. *Gynecol Oncol.* 2016;143(1):3–15.
97. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, Van Der Burg ME, Lacave AJ, Panici PB. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. *N Engl J Med.* 2010;363(10):943–53.
98. Chang S-J, Bristow RE, Chi DS, Cliby WA. Role of aggressive surgical cytoreduction in advanced ovarian cancer. *J Gynecol Oncol.* 2015;26(4):336–42.
99. Yallapu MM, Maher DM, Sundram V, Bell MC, Jaggi M, Chauhan SC. Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. *J Ovarian Res.* 2010;3(1):11.
100. Zhang J, Liu J, Xu X, Li L. Curcumin suppresses cisplatin resistance development partly via modulating extracellular vesicle-mediated transfer of MEG3 and miR-214 in ovarian cancer. *Cancer Chemother Pharmacol.* 2017;79(3):479–87.
101. Levy AS, Rathinavelu A, Coelho N, Ramnot A, Kanagasabai T, Bracho O, Smith R. Evaluation of the efficacy of curcumin and Y15 in platinum resistant ovarian cancer cells. In: *AACR*; 2018.
102. Sahin K, Orhan C, Tuzcu M, Sahin N, Tastan H, Özercan İH, Güler O, Kahraman N, Kucuk O, Ozpolat B. Chemopreventive and antitumor efficacy of curcumin in a spontaneously developing hen ovarian cancer model. *Cancer Prev Res.* 2018;11(1):59–67.
103. Weir NM, Selvendiran K, Kutala VK, Tong L, Vishwanath S, Rajaram M, Tridandapani S, Anant S, Kuppusamy P. Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. *Cancer Biol Ther.* 2007;6(2):178–84.
104. Liu L-D, Pang Y-X, Zhao X-R, Li R, Jin C-J, Xue J, Dong R-Y, Liu P-S. Curcumin induces apoptotic cell death and protective autophagy by inhibiting AKT/mTOR/p70S6K pathway in human ovarian cancer cells. *Arch Gynecol Obstetr.* 2019;299(6):1627–39.
105. Seo J-A, Kim B, Dhanasekaran DN, Tsang BK, Song YS. Curcumin induces apoptosis by inhibiting sarco/endoplasmic reticulum Ca<sup>2+</sup> ATPase activity in ovarian cancer cells. *Cancer Lett.* 2016;371(1):30–7.
106. Shi M, Cai Q, Yao L, Mao Y, Ming Y, Ouyang G. Antiproliferation and apoptosis induced by curcumin in human ovarian cancer cells. *Cell Biol Int.* 2006;30(3):221–6.
107. Lin YG, Kunnumakara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor- $\kappa$ B pathway. *Clin Cancer Res.* 2007;13(11):3423–30.
108. Ji C, Cao C, Lu S, Kivlin R, Amaral A, Kouttab N, Yang H, Chu W, Bi Z, Di W. Curcumin attenuates EGF-induced AQP3 up-regulation and cell migration in human ovarian cancer cells. *Cancer Chemother Pharmacol.* 2008;62(5):857–65.
109. Xiaoling M, Jing Z, Fang X, Liangdan T. Curcumin inhibits invasion and metastasis in the human ovarian cancer cells SKOV3 by CXCL12–CXCR4 axis. *Afr J Biotechnol.* 2010;9(48):8230–4.
110. Wahl H, Tan L, Griffith K, Choi M, Liu JR. Curcumin enhances Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells. *Gynecol Oncol.* 2007;105(1):104–12.
111. Cornelison R, Llaneza DC, Landen CN. Emerging therapeutics to overcome chemoresistance in epithelial ovarian cancer: A mini-review. *Int J Mol Sci.* 2017;18(10):2171.
112. He M, Wang D, Zou D, Wang C, Lopes-Bastos B, Jiang WG, Chester J, Zhou Q, Cai J. Re-purposing of curcumin as an anti-metastatic agent for the treatment of epithelial ovarian cancer: in vitro model using cancer stem cell enriched ovarian cancer spheroids. *Oncotarget.* 2016;7(52):86374–87.
113. Yen HY, Tsao CW, Lin YW, Kuo CC, Tsao CH, Liu CY. Regulation of carcinogenesis and modulation through Wnt/ $\beta$ -catenin signaling by curcumin in an ovarian cancer cell line. *Sci Rep.* 2019;9(1):17267.
114. Tian M, Tian D, Qiao X, Li J, Zhang L. Modulation of Myb-induced NF- $\kappa$ B–STAT3 signaling and resulting cisplatin resistance in ovarian cancer by dietary factors. *J Cell Physiol.* 2019;234(11):21126–34.
115. Kwon Y. Food-derived polyphenols inhibit the growth of ovarian cancer cells irrespective of their ability to induce antioxidant responses. *Heliyon.* 2018;4(8):e00753.
116. Choe SR, Kim YN, Park CG, Cho KH, Cho DY, Lee HY. RCP induces FAK phosphorylation and ovarian cancer cell invasion with inhibition by curcumin. *Exp Mol Med.* 2018;50(4):52.
117. Sahin K, Orhan C, Tuzcu M, Sahin N, Tastan H, Ozercan İH, Güler O, Kahraman N, Kucuk O, Ozpolat B. Chemopreventive and Antitumor Efficacy of Curcumin in a Spontaneously Developing Hen Ovarian Cancer Model. *Cancer Prev Res (Philadelphia, Pa).* 2018;11(1):59–67.
118. Zhao J, Pan Y, Li X, Zhang X, Xue Y, Wang T, Zhao S, Hou Y. Dihydroartemisinin and Curcumin Synergistically Induce Apoptosis in SKOV3 Cells Via Upregulation of miR-124 Targeting Midkine. *Cell Physiol Biochem.* 2017;43(2):589–601.
119. Zhao S-F, Zhang X, Zhang X-J, Shi X-Q, Yu Z-J, Kan Q-C. Induction of microRNA-9 mediates cytotoxicity of curcumin against SKOV3 ovarian cancer cells. *Asian Pac J Cancer Prev.* 2014;15(8):3363–8.
120. Lv J, Shao Q, Wang H, Shi H, Wang T, Gao W, Song B, Zheng G, Kong B, Qu X. Effects and mechanisms of curcumin and basil polysaccharide on the invasion of SKOV3 cells and dendritic cells. *Mol Med Rep.* 2013;8(5):1580–6.
121. Seo JH, Jeong KJ, Oh WJ, Sul HJ, Sohn JS, Kim YK, Kang JK, Park CG, Lee HY. Lysophosphatidic acid induces STAT3 phosphorylation and ovarian cancer cell motility: their inhibition by curcumin. *Cancer Lett.* 2010;288(1):50–6.
122. Montopoli M, Ragazzi E, Foldi G, Caparrotta L. Cell-cycle inhibition and apoptosis induced by curcumin and cisplatin or oxaliplatin in human ovarian carcinoma cells. *Cell Prolif.* 2009;42(2):195–206.
123. Pan W, Yang H, Cao C, Song X, Wallin B, Kivlin R, Lu S, Hu G, Di W, Wan Y. AMPK mediates curcumin-induced cell death in CaOV3 ovarian cancer cells. *Oncol Rep.* 2008;20(6):1553–9.
124. Yu Z, Wan Y, Liu Y, Yang J, Li L, Zhang W. Curcumin induced apoptosis via PI3K/Akt-signalling pathways in SKOV3 cells. *Pharm Biol.* 2016;54(10):2026–32.
125. Li-duan Q, Qiang-song T, Cui-huan W. Growth inhibition and apoptosis inducing mechanisms of curcumin on human ovarian cancer cell line A2780. *Chin J Integr Med.* 2006;12(2):126–31.
126. Yin Z, Sun J. Curcumin induces human SKOV3 cell apoptosis via the activation of Rho-kinase. *Eur J Gynaecol Oncol.* 2014;35(4):433–7.
127. Duse L, Agel MR, Pinnareddy SR, Schafer J, Selo MA, Ehrhardt C, Bakowsky U. Photodynamic Therapy of Ovarian Carcinoma Cells with Curcumin-Loaded Biodegradable Polymeric Nanoparticles. *Pharmaceutics.* 2019;11(6):282.
128. Ramezani T, Nabiuni M, Baharara J, Parivar K, Namvar F. Sensitization of Resistance Ovarian Cancer Cells to Cisplatin by Biogenic Synthesized Silver Nanoparticles through p53 Activation. *Iran J Pharm Res.* 2019;18(1):222–31.
129. Fatease AA, Shah V, Nguyen DX, Cote B, LeBlanc N, Rao DA, Alani AWG. Chemosensitization and mitigation of Adriamycin-induced cardiotoxicity using combinational polymeric micelles for co-delivery of quercetin/resveratrol and resveratrol/curcumin in ovarian cancer. *Nanomedicine.* 2019;19:39–48.
130. Seyed Hosseini E, Alizadeh Zarei M, Babashah S, Nakhaei Sistani R, Sadeghizadeh M, Haddad Kashani H, Amini Mahabadi J, Izadpanah F, Atlasi MA, Nikzad H. Studies on combination of oxaliplatin and dendrosomal nanocurcumin on proliferation, apoptosis induction, and long non-coding RNA expression in ovarian cancer cells. *Cell Biol Toxicol.* 2019;35(3):247–66.
131. Dwivedi P, Yuan S, Han S, Mangrio FA, Zhu Z, Lei F, Ming Z, Cheng L, Liu Z, Si T, et al. Core-shell microencapsulation of curcumin in PLGA microparticles: programmed for application in ovarian cancer therapy. *Artif Cells Nanomed Biotechnol.* 2018;46(sup3):S481–S491.
132. Liu Z, Zhu YY, Li ZY, Ning SQ. Evaluation of the efficacy of paclitaxel with curcumin combination in ovarian cancer cells. *Oncology Lett.* 2016;12(5):3944–8.

133. Liu L, Xiong X, Shen M, Ru D, Gao P, Zhang X, Huang C, Sun Y, Li H, Duan Y. Co-Delivery of Triptolide and Curcumin for Ovarian Cancer Targeting Therapy via mPEG-DPPE/CaP Nanoparticle. *J Biomed Nanotechnol*. 2018; 14(10):1761–72.
134. Du Z, Sha X. Demethoxycurcumin inhibited human epithelia ovarian cancer cells' growth via up-regulating miR-551a. *Tumour Biol*. 2017;39(3): 1010428317694302.
135. Baghbani F, Moztaaradeh F. Bypassing multidrug resistant ovarian cancer using ultrasound responsive doxorubicin/curcumin co-deliver alginate nanodroplets. *Colloids Surf B, Biointerfaces*. 2017;153:132–40.
136. Alberti D, Protti N, Franck M, Stefania R, Bortolussi S, Altieri S, Deagostino A, Aime S, Geninatti Crich S. Theranostic Nanoparticles Loaded with Imaging Probes and Rubrocurcumin for Combined Cancer Therapy by Folate Receptor Targeting. *ChemMedChem*. 2017;12(7):502–9.
137. Bondi ML, Emma MR, Botto C, Augello G, Azzolina A, Di Gaudio F, Craparo EF, Cavallaro G, Bachvarov D, Cervello M. Biocompatible Lipid Nanoparticles as Carriers To Improve Curcumin Efficacy in Ovarian Cancer Treatment. *J Agric Food Chem*. 2017;65(7):1342–52.
138. Steuber N, Vo K, Wadhwa R, Birch J, Iacoban P, Chavez P, Elbayoumi TA. Tocotrienol Nanoemulsion Platform of Curcumin Elicit Elevated Apoptosis and Augmentation of Anticancer Efficacy against Breast and Ovarian Carcinomas. *Int J Mol Sci*. 2016;17(11):1792.
139. Pei H, Yang Y, Cui L, Yang J, Li X, Yang Y, Duan H. Bisdemethoxycurcumin inhibits ovarian cancer via reducing oxidative stress mediated MMPs expressions. *Sci Rep*. 2016;6:28773.
140. Arzuman L, Beale P, Yu JQ, Huq F. Synthesis of tris (quinoline) monochloroplatinum (II) Chloride and its Activity Alone and in Combination with Capsaicin and Curcumin in Human Ovarian Cancer Cell Lines. *Anticancer Res*. 2016;36(6):2809–18.
141. Zhou L, Duan X, Zeng S, Men K, Zhang X, Yang L, Li X. Codelivery of SH-aspirin and curcumin by mPEG-PLGA nanoparticles enhanced antitumor activity by inducing mitochondrial apoptosis. *Int J Nanomedicine*. 2015;10:5205.
142. Scarano W, De Souza P, Stenzel MH. Dual-drug delivery of curcumin and platinum drugs in polymeric micelles enhances the synergistic effects: a double act for the treatment of multidrug-resistant cancer. *Biomater Sci*. 2015;3(1):163–74.
143. Gou Q, Liu L, Wang C, Wu Q, Sun L, Yang X, Xie Y, Li P, Gong C. Polymeric nanoassemblies entrapping curcumin overcome multidrug resistance in ovarian cancer. *Colloids Surf B Biointerfaces*. 2015;126:26–34.
144. Arzuman L, Beale P, Chan C, Yu JQ, Huq F. Synergism from combinations of tris (benzimidazole) monochloroplatinum (II) chloride with capsaicin, quercetin, curcumin and cisplatin in human ovarian cancer cell lines. *Anticancer Res*. 2014;34(10):5453–64.
145. Sarisozen C, Abouzeid AH, Torchilin VP. The effect of co-delivery of paclitaxel and curcumin by transferrin-targeted PEG-PE-based mixed micelles on resistant ovarian cancer in 3-D spheroids and in vivo tumors. *Eur J Pharm Biopharm*. 2014;88(2):539–50.
146. Abouzeid AH, Patel NR, Torchilin VP. Polyethylene glycol-phosphatidylethanolamine (PEG-PE)/vitamin E micelles for co-delivery of paclitaxel and curcumin to overcome multi-drug resistance in ovarian cancer. *Int J Pharm*. 2014;464(1–2):178–84.
147. Kumar SSD, Surianarayanan M, Vijayaraghavan R, Mandal AB, Macfarlane DR. Curcumin loaded poly (2-hydroxyethyl methacrylate) nanoparticles from gelled ionic liquid–In vitro cytotoxicity and anti-cancer activity in SKOV-3 cells. *Eur J Pharm Sci*. 2014;51:34–44.
148. Qu W, Xiao J, Zhang H, Chen Q, Wang Z, Shi H, Gong L, Chen J, Liu Y, Cao R. B19, a novel monocarbonyl analogue of curcumin, induces human ovarian cancer cell apoptosis via activation of endoplasmic reticulum stress and the autophagy signaling pathway. *Int J Biol Sci*. 2013;9(8):766.
149. Saxena V, Hussain MD. Polymeric mixed micelles for delivery of curcumin to multidrug resistant ovarian cancer. *J Biomed Nanotechnol*. 2013;9(7):1146–54.
150. Kanai M, Imaizumi A, Otsuka Y, Sasaki H, Hashiguchi M, Tsujiko K, Matsumoto S, Ishiguro H, Chiba T. Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers. *Cancer Chemother Pharmacol*. 2012;69(1):65–70.
151. Ravindranath V, Chandrasekhara N. In vitro studies on the intestinal absorption of curcumin in rats. *Toxicology*. 1981;20(2–3):251–7.
152. Ireson CR, Jones DJ, Orr S, Coughtrie MW, Boocock DJ, Williams ML, Farmer PB, Steward WP, Gescher AJ. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. *Cancer Epidemiol Biomarkers Prev*. 2002;11(1):105–11.
153. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, Pirmohamed M, Marnett LJ, Gescher AJ, Steward WP. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. *Clin Cancer Res*. 2001;7(7):1894–900.
154. Sharma RA, Euden SA, Platten SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. *Clin Cancer Res*. 2004;10(20):6847–54.
155. Garcea G, Jones D, Singh R, Dennison A, Farmer P, Sharma R, Steward W, Gescher A, Berry D. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. *Br J Cancer*. 2004;90(5):1011–5.
156. Cheng A, Hsu C, Lin J, Hsu M, Ho Y, Shen T, Ko J, Lin J, Lin B, Wu M. Phase I Clinical Trial of Curcumin, a Chemopreventive Agent. Patients with High-risk of Pre-malignant Lesions. *Anticancer Res*. 2001;21:2895–001.
157. Lao CD, Ruffin MT, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL, Brenner DE. Dose escalation of a curcuminoid formulation. *BMC Complement Altern Med*. 2006;6(1):1–4.
158. Soni S, Ak B, Rk S, Maitra A. Delivery of hydrophobised 5-fluorouracil derivative to brain tissue through intravenous route using surface modified nanogels. *J Drug Target*. 2006;14(2):87–95.
159. Rai M, Pandit R, Gaikwad S, Yadav A, Gade A. Potential applications of curcumin and curcumin nanoparticles: from traditional therapeutics to modern nanomedicine. *Nanotechnol Rev*. 2015;4(2):161–72.
160. Mahal A, Wu P, Jiang ZH, Wei X. Synthesis and Cytotoxic Activity of Novel Tetrahydrocurcumin Derivatives Bearing Pyrazole Moiety. *Nat Prod Bioprospect*. 2017;7(6):461–9.
161. Momtazi AA, Sahebkar A. Difluorinated curcumin: A promising curcumin analogue with improved anti-tumor activity and pharmacokinetic profile. *Current Pharmaceutical Design*. 2016;22(28):4386–97.
162. Tripathi A, Misra K. Designing and development of novel curcumin analogues/congeners as inhibitors of breast cancer stem cells growth. *Chem Eng Trans*. 2016;49:79–84.
163. Borik RM, Fawzy NM, Abu-Bakr SM, Aly MS. Design, Synthesis, Anticancer Evaluation and Docking Studies of Novel Heterocyclic Derivatives Obtained via Reactions Involving Curcumin. *Molecules (Basel, Switzerland)*. 2018;23(6): 1398.
164. Hackler L Jr, Ozsvari B, Gyuris M, Sipos P, Fabian G, Molnar E, Marton A, Farago N, Mihaly J, Nagy LI, et al. The Curcumin Analog C-150, Influencing NF-kappaB, UPR and Akt/Notch Pathways Has Potent Anticancer Activity In Vitro and In Vivo. *PLoS one*. 2016;11(3):e0149832.
165. Gryniewicz G, Slifirski P. Curcumin and curcuminoids in quest for medicinal status. *Acta biochimica Polonica*. 2012;59(2):201–12.
166. Bhattacharyya U, Kumar B, Garai A, Bhattacharyya A, Kumar A, Banerjee S, Kondaiah P, Chakravarty AR. Curcumin "Drug" Stabilized in Oxidovanadium (IV)-BODIPY Conjugates for Mitochondria-Targeted Photocytotoxicity. *Inorg Chem*. 2017;56(20):12457–68.
167. Liu Y, Zhou J, Hu Y, Wang J, Yuan C. Curcumin inhibits growth of human breast cancer cells through demethylation of DLCL1 promoter. *Mol Cell Biochem*. 2017;425(1–2):47–58.
168. Zhang J, Feng Z, Wang C, Zhou H, Liu W, Kanchana K, Dai X, Zou P, Gu J, Cai L, et al. Curcumin derivative WZ35 efficiently suppresses colon cancer progression through inducing ROS production and ER stress-dependent apoptosis. *Am J Cancer Res*. 2017;7(2):275–88.
169. Shehzad A, Khan S, Shehzad O, Lee YS. Curcumin therapeutic promises and bioavailability in colorectal cancer. *Drugs Today (Barc)*. 2010;46(7):523–32.
170. Somers-Edgar TJ, Taurin S, Larsen L, Chandramouli A, Nelson MA, Rosengren RJ. Mechanisms for the activity of heterocyclic cyclohexanone curcumin derivatives in estrogen receptor negative human breast cancer cell lines. *Invest New Drugs*. 2011;29(1):87–97.
171. Kumar AP, Garcia GE, Ghosh R, Rajnarayanan RV, Alworth WL, Slaga TJ. 4-Hydroxy-3-methoxybenzoic acid methyl ester: a curcumin derivative targets Akt/NF kappa B cell survival signaling pathway: potential for prostate cancer management. *Neoplasia (New York, NY)*. 2003;5(3):255–66.
172. Pan M-H, Huang T-M, Lin J-K. Biotransformation of curcumin through reduction and glucuronidation in mice. *Drug Metab Dispos*. 1999;27(4):486–94.
173. Heger M, van Golen RF, Broekgaarden M, Michel MC. The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer. *Pharmacol Rev*. 2014;66(1):222–307.

174. Sandur SK, Pandey MK, Sung B, Ahn KS, Murakami A, Sethi G, Limtrakul P, Badmaev V, Aggarwal BB. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. *Carcinogenesis*. 2007;28(8):1765–73.
175. Somparn P, Phisalaphong C, Nakornchai S, Unchern S, Morales NP. Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivatives. *Biol Pharm Bull*. 2007;30(1):74–8.
176. Prasad S, Tyagi AK, Aggarwal BB. Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. *Cancer Res Treat*. 2014;46(1):2.
177. Pal A, Sung B, Prasad BAB, Schuber PT Jr, Prasad S, Aggarwal BB, Bornmann WG. Curcumin glucuronides: Assessing the proliferative activity against human cell lines. *Bioorg Med Chem*. 2014;22(1):435–9.
178. Xu H, Gong Z, Zhou S, Yang S, Wang D, Chen X, Wu J, Liu L, Zhong S, Zhao J. Liposomal curcumin targeting endometrial Cancer through the NF- $\kappa$ B pathway. *Cell Physiol Biochem*. 2018;48(2):569–82.
179. Hosseini ES, Zarei MA, Babashah S, Sistani RN, Sadeghizadeh M, Kashani HH, Mahabadi JA, Izadpanah F, Atlasi MA, Nikzad H. Studies on combination of oxaliplatin and dendrosomal nanocurcumin on proliferation, apoptosis induction, and long non-coding RNA expression in ovarian cancer cells. *Cell Biol*. 2019;35(3):247–66.

### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

